Henry Schein Stock Symbol and Financial Overview

Henry Schein is a well-established company with a rich history dating back to 1932. It's a Fortune 500 company that specializes in providing healthcare solutions to various industries.

The company's stock symbol is HSIC, which is listed on the NASDAQ stock exchange. This is the ticker symbol you'll see when researching or trading Henry Schein stock.

Henry Schein's financial performance is quite impressive, with a market capitalization of over $13 billion. This gives the company a significant presence in the market.

The company's revenue has consistently grown over the years, with a strong focus on innovation and expansion into new markets.

Take a look at this: Black Rifle Coffee Stock Symbol

Henry Schein's revenue was $12.34 billion in 2023, a decrease of -2.44% from the previous year. This decline in revenue is a significant trend to note.

Their net sales in 2024 are projected to be $12.78 billion, with a steady decline to $10.23 billion by 2025. This downward trend is concerning.

In 2024, Henry Schein's net income is estimated to be $422 million, a decrease from the previous year. This decrease in net income is a red flag.

Their net debt is also a concern, with an estimated $2.56 billion in 2023. This high level of debt can make it difficult for the company to invest in new projects or pay off debts.

Here's a breakdown of Henry Schein's financials:

Their stock price has been on the rise, with a 5-day change of +0.84% and a 1st Jan change of +1.77%. This increase in stock price is a positive trend.

Henry Schein's market capitalization is $10,046,794, making it a significant player in the market.

Here's an interesting read: Stock Price

Analysts are overwhelmingly bullish on Henry Schein stock, with 9 out of 10 analysts recommending a "Buy" rating.

The average analyst rating is "Buy" with a 12-month stock price forecast of $80.33, which is a decrease of -1.13% from the latest price.

See what others are reading: Buy Gesi Stock

Analysts have been consistently recommending Henry Schein stock over the past year, with a majority of them maintaining a "Buy" rating.

According to the analyst forecast, the 12-month stock price forecast is $80.33, which is a decrease of -1.13% from the latest price.

Here's a breakdown of the analyst ratings:

The analysts' recommendations have been varied, with some upgrading their ratings to "Buy" while others maintained their "Hold" or "Sell" ratings.

Private-equity firm KKR has taken a large stake in Henry Schein. KKR plans to work with Henry Schein to improve its operations.

KKR is expected to gain board seats as part of the deal. This move will likely impact Henry Schein's future direction and decision-making processes.

The Wall Street Journal reported on this development, providing insight into the partnership between KKR and Henry Schein.

KKK has taken a large stake in Henry Schein, a distributor of healthcare products. The private-equity firm plans to work with Henry Schein to improve its operations.

The Wall Street Journal reported on this development, indicating a significant move by KKR. Henry Schein's operations will likely undergo changes as a result.

KKR's involvement may lead to increased profitability for Henry Schein, as the firm aims to improve the company's operations. Ananym Capital Management, another investor, is also pushing for changes at Henry Schein.

Henry Schein has had a consistent track record of releasing earnings reports, with the most recent being Q3 2024 Earnings Release, which reported an actual EPS of 0.780 USD on November 5, 2024.

The company's earnings reports have shown fluctuations in actual EPS over the years, with the highest being 1.160 USD in Q2 2022. This suggests that Henry Schein's financial performance can be unpredictable.

In terms of actual EPS, Henry Schein's Q1 2023 Earnings Release reported 0.910 USD, while Q4 2022 Earnings Release reported 0.340 USD. This indicates a significant difference between the company's financial performance in the first and fourth quarters of 2022.

See what others are reading: Brighthouse Financial Stock Symbol

Here is a list of Henry Schein's recent earnings reports, including the actual EPS for each quarter:

Henry Schein's Annual General Meetings have also been a significant event, with the highest actual EPS reported being 4.450 USD in 2022.

If you're considering investing in Henry Schein stock, you'll want to know the basics. The stock symbol is HSIC.

As of the latest information available, Henry Schein's market capitalization is around $30 billion.

Investors can buy and sell Henry Schein stock on major exchanges like the NASDAQ.

Henry Schein plans to participate in investor conferences in November.

You can expect to hear from Henry Schein in November as they attend investor conferences.

If you're looking for a sense of how well a particular company is doing, you can take a look at its shareholder returns. Over the past 7 days, HSIC returned 5.9%.

The company has actually been doing quite well over the past year, with a return of 5.9%. This is significantly higher than the US Healthcare industry, which returned 1.7% over the same period.

Here's a quick comparison of HSIC's returns to the US Market and the US Healthcare industry over the past year:

HSIC actually underperformed the US Market, which returned 22.2% over the past year.

The valuation of Henry Schein stock is an important factor to consider for investors. The company's market capitalization has fluctuated between $8.05B and $14.38B over the past few years, with a current value of $10.05B.

The P/E ratio, which is a widely used metric to evaluate a company's stock, has decreased from 25.1x in 2024 to 19.3x in 2025. This indicates a potential decrease in the stock price.

Analysts have provided various estimates for the company's revenue and earnings. According to Example 2, the average estimate for Henry Schein's earnings is $1.21, with a growth rate estimate of 83.33% year over year.

A table summarizing the average revenue estimates for Henry Schein is as follows:

These estimates are based on the average of 13 analysts' predictions for 2026 and 12 analysts' predictions for 2027.

Analysts have also provided a 12-month stock price forecast of $80.33, which is a decrease of -1.13% from the latest price (Example 3). This forecast is based on the average rating of "Buy" from 9 analysts.